Business Wire - November 15, 2004
Dr. Stewart Lonky attended St. Lawrence University in Canton, New York, where he received his bachelor's degree in chemistry, and then went on to earn his medical degree at the State University of New York, Downstate Medical Center in 1971. Dr. Lonky has been a practicing physician in the Los Angeles area since 1982. He is Board Certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine. Prior to entering practice, Dr. Lonky served as a full-time faculty member at the University of California, San Diego in the Department of Medicine, Pulmonary Division, where he was engaged in research in the biochemistry of lung injury. He was a National Institutes of Health (NIH) Postdoctoral Fellow from 1974-77. He published over twenty articles and abstracts in the peer-reviewed literature during that time, and authored two book chapters.
Dr. Lonky founded the Trylon Corporation with his brothers in 1985, and has served as the Chief Medical Officer of that company since 1990. This company has developed diagnostic products for the early diagnosis of cervical and oral cancer, and Dr. Lonky's responsibilities have included product development, the direction of clinical research and interacting with regulatory agencies, including the U.S. Food and Drug Administration (FDA). In these roles he has been instrumental in successfully bringing a number of products to the medical marketplace. He has continued to be engaged in both clinical and biochemical research, and has published research articles in the peer-reviewed literature in the areas of cervical cancer and cellular pathophysiology. Since the company's products are cleared for marketing in a number of foreign countries, Dr. Lonky has experience in clinical research and regulatory affairs abroad.
Dr. Lonky earned his Masters in Business Administration (MBA) from Pepperdine University in 1993, and has lectured at Pepperdine in the executive MBA program in the past. He has also served on the Corporate Advisory Board of a National Nurse Practitioner's Association and served on the Medical Advisory Board of an international nutrition company. Dr. Lonky continues to make his home in Southern California.
"Working with a company like Nutra Pharma is exciting for me, because it is on the threshold of making important contributions to medicine in a very practical way," commented Dr. Stewart Lonky. "The company's target areas of research are in clinically important areas that affect large numbers of people in many countries. That alone is a reason for me to want to team up with Nutra Pharma. When you add to that the innovative approaches of the technologies we are working with, you have a prescription for success," he added.
"Dr. Lonky's background in the medical device arena and his understanding of the FDA regulatory environment will prove to be invaluable resources to Nutra Pharma," stated Rik Deitsch, Nutra Pharma's Chairman and Chief Executive Officer. "I'm very excited to be working with Dr. Lonky. He adds necessary experience to the Board that will allow Nutra Pharma to move from its development stage into the marketplace to accomplish our goals of near-term revenues," he concluded.
Commenting on how he envisions his contribution to the Company, Dr. Lonky stated, "I believe that the skills I have developed over the past 20 years at Trylon will mesh seamlessly with the needs of Nutra Pharma at this stage of its development. I am looking forward to rolling up my sleeves and helping to move our technologies to the market."
Dr. Lonky serves on the Board of Directors of Nutra Pharma effective November 11, 2004.
About Nutra Pharma Corp.
The Company's minority-owned subsidiary, ReceptoPharm, Inc, is developing technologies for the development of drugs for HIV and Multiple Sclerosis ("MS"). The Company's other holding Infectech, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.nutrapharma.com
Safe Harbor under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, regulatory approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties as may be detailed in the Company's filings with the Securities and Exchange Commission. Nothing in this press release shall be construed as an offer to buy or sell any securities herein.
CONTACT: Equitilink LLC
Andrew Arms, 877-788-1940
IR@nutrapharma.com
SOURCE: Nutra Pharma Corp.
041115
BW041107
Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .